EUVIMEDEUVIMED entdecken
Crossref

The impact of systemic therapy with gemcitabine and platinum in comparison with docetaxel on hematological parameters in patients with lung cancer: A four-year retrospective comparative study

Vildana Torlak-Arnautović, Ajla Torlak-Omerčević, Hana Torlak, Mirza Omerčević

Respiratio · 2026 · 16 (1-2) · 29-34

DOI: 10.5937/respira2602029t ↗

Kurz gefasst

Fachartikel in der Zeitschrift Respiratio, 2026. Verfasst von Vildana Torlak-Arnautović und 3 weiteren Autor:innen. Die Arbeit nennt 12 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Hematologic toxicity is a major limiting factor of systemic chemotherapy.

Aim

To compare the effects of gemcitabine plus platinum (Gem+Pt) and docetaxel on hematologic parameters and clinical outcomes.

Methods

This retrospective comparative study included patients treated over a four-year period. Hemoglobin, leukocytes, and platelets were analyzed at baseline, after 2 and 4 cycles. Neutropenia was defined as absolute neutrophil count (ANC) <1000/µL. Clinical outcomes included transfusions and treatment delays. Statistical analysis included Student's t-test and chi-square test. ROC analysis was performed on the overall study population.

Results

Both regimens led to a decline in hematologic parameters. The Gem+Pt group showed a more pronounced decrease in hemoglobin and platelets (p<0.05). Neutropenia was more frequent in the docetaxel group (53.8% vs. 20.8%). No significant difference was observed in severe thrombocytopenia. Red blood cell transfusions were more frequent in the Gem+Pt group, while treatment delays were comparable.

Conclusion

Gemcitabine plus platinum is associated with a more pronounced early hematologic decline, whereas docetaxel is associated with higher rates of neutropenia.

Zitieren

APA

Torlak-Arnautović, V., Torlak-Omerčević, A., Torlak, H., & Omerčević, M. (2026). The impact of systemic therapy with gemcitabine and platinum in comparison with docetaxel on hematological parameters in patients with lung cancer: A four-year retrospective comparative study. Respiratio, 16(1-2), 29-34. https://doi.org/10.5937/respira2602029t

Vancouver

Torlak-Arnautović V, Torlak-Omerčević A, Torlak H, Omerčević M. The impact of systemic therapy with gemcitabine and platinum in comparison with docetaxel on hematological parameters in patients with lung cancer: A four-year retrospective comparative study. Respiratio. 2026;16(1-2):29-34. doi:10.5937/respira2602029t

BibTeX
@article{TorlakArnautovi2026,
  author = {Torlak-Arnautović, Vildana and Torlak-Omerčević, Ajla and Torlak, Hana and Omerčević, Mirza},
  title = {The impact of systemic therapy with gemcitabine and platinum in comparison with docetaxel on hematological parameters in patients with lung cancer: A four-year retrospective comparative study},
  journal = {Respiratio},
  year = {2026},
  volume = {16},
  number = {1-2},
  pages = {29--34},
  doi = {10.5937/respira2602029t}
}
Kostenlos starten →